ストックスクリーナーアプリを入手
2.13
2.74%
-0.06
アフターアワーズ：
2.13
前日終値:
$2.19
開ける：
$2.18
24時間の取引高:
663.14K
Relative Volume:
0.87
時価総額：
$122.03M
収益：
$70.00M
当期純損益:
$22.37M
株価収益率:
5.5994
EPS:
0.3804
ネットキャッシュフロー:
$29.61M
1週間 パフォーマンス:
-0.93%
1か月 パフォーマンス:
-14.80%
6か月 パフォーマンス:
-37.35%
1年 パフォーマンス:
+33.96%
1日の値動き範囲:
$2.12
$2.275
1週間の範囲:
$2.06
$2.275
52週間の値動き範囲:
$1.195
$4.94
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
名前
Black Diamond Therapeutics Inc
セクター
電話
617-417-5868
住所
245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA
Compare BDTX vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
2.13 | 125.46M | 70.00M | 22.37M | 29.61M | 0.3804 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-11-18 | 再開されました | Piper Sandler | Overweight |
| 2025-10-16 | 再開されました | Stifel | Buy |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2025-07-01 | 再開されました | Raymond James | Outperform |
| 2024-07-31 | 開始されました | Raymond James | Outperform |
| 2023-07-14 | 開始されました | Piper Sandler | Overweight |
| 2023-06-30 | アップグレード | Stifel | Hold → Buy |
| 2023-06-28 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-06-27 | アップグレード | Wedbush | Neutral → Outperform |
| 2022-03-29 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-03-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-09-30 | 開始されました | Stifel | Hold |
| 2021-01-07 | 開始されました | Wedbush | Outperform |
| 2020-11-24 | 開始されました | Berenberg | Buy |
| 2020-05-04 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-24 | 開始されました | Canaccord Genuity | Buy |
| 2020-02-24 | 開始されました | Cowen | Outperform |
| 2020-02-24 | 開始されました | JP Morgan | Overweight |
| 2020-02-24 | 開始されました | Jefferies | Buy |
すべてを表示
Black Diamond Therapeutics Inc (BDTX) 最新ニュース
Aug Macro: Will Black Diamond Therapeutics Inc benefit from rate cuts2026 Drop Watch & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Wedbush bullish on Black Diamond Therapeutics (BDTX) following progress in Silevertinib program - MSN
Black Diamond Therapeutics: Market Is Yawning About These Data, But I See Opportunity - Seeking Alpha
Top 5 Stocks Under $5 That Could Triple - Insider Monkey
Technical Analysis: Will Black Diamond Therapeutics Inc benefit from AI trendsQuarterly Profit Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
Volume Summary: Can Black Diamond Therapeutics Inc maintain sales growthDollar Strength & Low Risk High Reward Ideas - baoquankhu1.vn
Exit Recap: Is Black Diamond Therapeutics Inc stock good for income investorsMarket Movement Recap & AI Optimized Trade Strategies - baoquankhu1.vn
Black Diamond (BDTX) director receives 6,919-share stock grant - Stock Titan
Black Diamond Therapeutics (BDTX) director receives 6,105-share stock grant in lieu of cash - Stock Titan
VIX Spike: Is Black Diamond Therapeutics Inc part of any ETFEarnings Trend Report & Low Risk High Reward Ideas - baoquankhu1.vn
EV Market: Is Black Diamond Therapeutics Inc benefiting from interest rate changesQuarterly Profit Review & Technical Pattern Based Buy Signals - baoquankhu1.vn
BDTX Stock Price, Quote & Chart | BLACK DIAMOND THERAPEUTICS I (NASDAQ:BDTX) - ChartMill
Stock Ratings | Baird Bank raises CRCL's price target to $138; Rodman & Renshaw initiates coverage of BTAI with a "buy" recommendation and a $17 price target, representing a potential upside of 882.66%. - Sahm
Piper Sandler Sticks to Its Buy Rating for Black Diamond Therapeutics (BDTX) - The Globe and Mail
Black Diamond Therapeutics (BDTX) Profit Swing To US$0.81 EPS Challenges Bearish Earnings Narratives - simplywall.st
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Black Diamond Therapeutics (BDTX) Receives a Buy from TD Cowen - The Globe and Mail
Investment Recap: Does Black Diamond Therapeutics Inc align with a passive investing strategy2026 Setups & Weekly High Potential Alerts - baoquankhu1.vn
BDTX: Wedbush Raises Price Target, Maintains Outperform Rating | - GuruFocus
Wedbush Forecasts Strong Price Appreciation for Black Diamond Therapeutics (NASDAQ:BDTX) Stock - MarketBeat
Wedbush Lifts Price Target on Black Diamond Therapeutics to $14 From $13, Keeps Outperform Rating - marketscreener.com
Black Diamond: Fourth Quarter Financial Results Overview - Bitget
Black Diamond Therapeutics 2025 Annual Report – Clinical-Stage Oncology Pipeline, MasterKey Therapies, and Regulatory Overview - Minichart
Black Diamond Therapeutics (BDTX) Advances Silevertinib Trials i - GuruFocus
Black Diamond Therapeutics (NASDAQ:BDTX) Issues Quarterly Earnings Results - MarketBeat
Black Diamond: Q4 Earnings Snapshot - 10TV
BDTX: Strong clinical and financial performance, with silevertinib advancing and cash runway to 2028 - TradingView
Silevertinib data and Servier pact shape Black Diamond (NASDAQ: BDTX) - Stock Titan
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - The Manila Times
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
[8-K] Black Diamond Therapeutics, Inc. Reports Material Event | BDTX SEC FilingForm 8-K - Stock Titan
Cancer drug hitting 60% response rate now funded into 2028 - Stock Titan
Black Diamond Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
BDTX (Black Diamond Therapeutics) NonCurrent Deferred Reven - GuruFocus
DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier - Finviz
Published on: 2026-03-07 03:01:03 - baoquankhu1.vn
Black Diamond Therapeutics Teases Next-Quarter PFS Data for Silevertinib at TD Cowen Conference - MarketBeat
Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug? - MSN
Downgrade Watch: Whats the profit margin of Black Diamond Therapeutics IncWeekly Market Summary & Real-Time Stock Entry Alerts - baoquankhu1.vn
BDTX: Silevertinib demonstrates robust efficacy in NSCLC and is advancing to pivotal GBM trials - TradingView
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors - Quantisnow
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - Sahm
Black Diamond Therapeutics Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Clinical-stage oncology firm Black Diamond sets 3 investor events - Stock Titan
Revenue Check: Is Black Diamond Therapeutics Inc a strong growth stock2025 Investor Takeaways & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
BDTX PE Ratio & Valuation, Is BDTX Overvalued - Intellectia AI
Hedge Fund Bets: Is Black Diamond Therapeutics Inc a strong growth stock2025 Key Highlights & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Black Diamond Therapeutics (BDTX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Analysts Are Neutral on These Healthcare Stocks: Pliant Therapeutics (PLRX), Summit Therapeutics (SMMT) - The Globe and Mail
BDTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BDTX SEC FilingsBlack Diamond Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Black Diamond Therapeutics Inc (BDTX) 財務データ
収益
当期純利益
現金流量
EPS
0.04%
0.06%
大文字化:
|
ボリューム (24 時間):